Gmax Biopharm LLC

Zhejiang University

Otis Elevator Company

Gmaz Biopharm LLC

Chint Solar (zhejiang) Co., Ltd.

Hua Zhang

Min Wang

Cheng Zhang

Shuqian Jing

Xiaofeng Wang

Chenjiang Yao

Yan Jiang

Xinxin Shi

Hao Pan

Donghong Liu

Xingqian Ye

Shiguo Chen

QingXi Cai

Jiaqi Zheng

Chong Chen

Minghua Wang

Junfeng Wu

Rongzhu Wang

Liangliang Bi

Lei Sun

Liyou Yang

Zhanwei Qiu

Jianbo Jin

Tao Feng

Yongmin Zhu

Weizhi Han

Jinyan Hu

Shiyong Liu

Junmei Rong

Lan Ding

Cao Yu

Xinwei Niu

Huanfeng Liu

Yongtao Yang

Yong Guo

Kesuo Fan

Provided herein are an apelin receptor (APJ) antibody and its fusion protein with Elabela. Also provided herein is a pharmaceutical composition of a fusion protein with APJ antibody and Elabela, and use thereof in treating, preventing, or alleviating one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension or one or more symptoms of heart failure.

APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01

Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.

GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof

The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.

Human endothelin receptor antibody and use thereof

Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.

GCGR antibody and GLP-1 fusion protein thereof, pharmaceutical composition thereof and application thereof

The present disclosure discloses a method for extracting a RG-I-rich pectic polysaccharide. The method comprises the following steps: mixing and stirring a citrus fruit peel powder and a dilute hydrochloric acid solution at a low temperature to destroy cell walls of citrus peels, filtering, and then mixing the retentate with a sodium hydroxide solution for low temperature extraction, adding ethanol to the solution obtained by filtering to precipitate, and washing the obtained polysaccharide with ethanol and drying to obtain the above pectic polysaccharide. Compared with the traditional extraction method, this method reduces the hydrolysis of pectin side chains by controlling the extraction temperature, and the extracted pectic polysaccharide is rich in RG-I domain and has higher biological activity such as cancer and cardiovascular disease prevention. Energy can be greatly saved because of the low extraction temperature. The extracted pectic polysaccharide can be potentially used as functional food ingredients.

Method for extracting RG-I-rich pectin

The present disclosure discloses a method for preparing a citrus-derived complex prebiotic agent. The method comprises the following steps: removing external citrus peels after blanching citrus fruits with hot water, soaking citrus segments after splitting with an acid solution and an alkali solution to remove membranes of the citrus segments, and adjusting the pH of the obtained alkali soaking water with acid soaking water or acid to be weakly acidic or neutral to obtain the complex prebiotic agent, which has the function of reversing intestinal flora disorders. Compared with the traditional prebiotic product preparing method, the product prepared by the method contains prebiotic functional components with different targets such as pectin, flavonoids, oligosaccharides, and other fibers at the same time, and has the efficacies of regulating intestinal flora and reversing intestinal flora disorders caused by antibiotics. At the same time, the preparing method has the characteristics of simple operation and low cost, perfectly supplements a comprehensive utilization process of citrus fruit processing, solves the discharge problem of citrus fruit processing water, and generates very good social benefits.

Method for preparing citrus-derived complex prebiotic agent and use of the same

Disclosed is a stable pharmaceutical solution formulation of a GLP-1R antibody fusion protein, comprising a therapeutically effective amount of the GLP-1R antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mM, the final concentration of the surfactant is 0.01%-0.5%, and the pH value of the stable solution formulation is from 5.0 to 8.0. The stable solution formulation of the present invention can be used in the treatment of diabetes, obesity and conditions associated therewith.

Stable pharmaceutical solution formulation of GLP-1R antibody fusion protein

Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.

Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1

The present invention relates to a landing-door door lock device. The following problem is solved: the position of a lock ball of a general landing-door door lock device is not adjustable, and adjustment is complicated when there is a deviation between positions of the lock ball and a door knife. The device includes a primary lock and a secondary lock, the primary lock includes a bottom plate and a locking arm, a counter weight is mounted on the locking arm, a moving ball is fixed onto the counter weight, a fixed ball is mounted on the bottom plate, the secondary lock includes a buckle plate, the locking arm is connected onto the bottom plate through a rotary shaft, an arc-shaped hole is opened on the counter weight, a shaft sleeve is sheathed on a shaft of the fixed ball, the shaft sleeve penetrates into the arc-shaped hole, a front end of the buckle plate is provided with a first lock hook, the locking arm is correspondingly provided thereon with a lock column, and the first lock hook is buckled on the lock column. The present invention has the following advantages: the rotary shaft and the fixed ball are disposed separately, the positions of the fixed ball and the moving ball can be adjusted left and right, when there is a deviation between positions of the lock ball and the door knife of the landing-door door lock device on different floors, it is not necessary to adjust the position of the door lock of the whole floor, so adjustment is simple, and a problem of poor contact occurring in electrical contacts on the door lock is also avoided.

Landing-door door lock device

Antibody specifically binding to GLP-1 R and fusion protein thereof with GLP-1

The present invention discloses a method of fabricating a heterojunction battery, comprising the steps of: depositing a first amorphous silicon intrinsic layer on the front of an n-type silicon wafer, wherein the n-type silicon wafer may be a monocrystal or polycrystal silicon wafer; depositing an amorphous silicon p layer on the first amorphous silicon intrinsic layer; depositing a first boron doped zinc oxide thin film on the amorphous silicon p layer; forming a back electrode and an Al-back surface field on the back of the n-type silicon wafer; and forming a positive electrode on the front of the silicon wafer. In addition, the present invention further discloses a method of fabricating a double-sided heterojunction battery. In the present invention, the boron doped zinc oxide is used as an anti-reflection film in place of an ITO thin film; due to the special nature, especially the light trapping effect of the boron doped zinc oxide, the boron doped zinc oxide can achieve good anti-reflection. Therefore, the step of texturization is removed and the fabrication process simplified. As polycrystal silicon texturization is more challenging, the present invention is of more significance to heterojunction batteries using a polycrystal silicon wafer.

Method of fabricating heterojunction battery

Growing community of inventors

Hangzhou, China

Hua Zhang